Study of CYFRA 21-1 Concentration in Patients with Lung Cancer Based on the Pathological Type

Document Type : Original Article(s)

Authors

1 Professor, Infectious Diseases and Tropical Medicine Research Center, Department of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Tumor markers are not recommended for early diagnosis of lung cancer due to their low sensitivity, but they could be used as a determining tool to differentiate malignancies from benign tumors. Therefore, this study was conducted to measure the serum concentration of the CYFRA biomarker in patients with lung cancer.
Methods: In this cross-sectional study conducted in 2022 at a superspecialty hospital in Esfahan, 12 patients were included. All participants consented to be in the study, and the ethical committee of the national health ministry authorized ethical issues. Blood samples were collected from participants to measure the CYFRA 21 level using electrochemiluminescence (ECL) with German assay kits from ROCH. Blood samples were taken prior to therapy initiation and after the diagnosis confirmation by a pulmonologist.
Findings: The minimum age was 44 years and the maximum age was 78 years old.50 % of the individuals were men. The mean CYFRA 21-1 level was 8.2358 IU/dL. The minimum level was 0.70 and the maximum level was 56.70 IU/dL. Pathologic results demonstrated that 25% of the samples were squamous cell carcinoma (SCC), 8.3% were small cell carcinoma (SmCC), and 58.3% were adenocarcinoma.
Conclusion: According to the study findings, lung adenocarcinoma has the highest Mean CYFRA 21-1 level, followed by SMCC and then SCC. Also, females and the age group of 66-78 years had the highest mean serum concentration of CYFRA 21-1. However, due to the small sample size of our study, it is suggested that this study be repeated with a larger sample size.

Highlights

Azar Baradaran: Google Scholar 

Keywords

Main Subjects

References

  1. Khazaei S, Mansori K, Soheylizad M, Gholamaliee B, Khosravi Shadmani F, Khazaei Z, et al. Epidemiology of Lung Cancer in Iran: Sex Difference and Geographical Distribution. Middle East Journal of Cancer 2017;8(4): 223-8.
  2. Fathi Z, Syn NL, Zhou JG, Roudi R. Molecular epidemiology of lung cancer in Iran: implications for drug development and cancer prevention. J Hum Genet 2018; 63(7): 783-94.
  3. Yu Y, Qian L, Cui J. Value of neutrophil-to-lymphocyte ratio for predicting lung cancer prognosis: A meta-analysis of 7,219 patients. Mol Clin Oncol 2017; 7(3): 498-506.
  4. Calabrò L, Peters S, Soria JC, Di Giacomo AM, Barlesi F, Covre A, et al. Challenges in lung cancer therapy during the COVID-19 pandemic. Lancet Respir Med 2020; 8(6): 542-4.
  5. Cassim S, Chepulis L, Keenan R, Kidd J, Firth M, Lawrenson R. Patient and carer perceived barriers to early presentation and diagnosis of lung cancer: a systematic review. BMC Cancer 2019; 19(1): 25.
  6. Gildea TR, DaCosta Byfield S, Hogarth DK, Wilson DS, Quinn CC. A retrospective analysis of delays in the diagnosis of lung cancer and associated costs. Clinicoecon Outcomes Res 2017; 9: 261-9.
  7. Li Y, Tian X, Gao L, Jiang X, Fu R, Zhang T, et al. Clinical significance of circulating tumor cells and tumor markers in the diagnosis of lung cancer. Cancer Med 2019; 8(8): 3782-92.
  8. Liu L, Teng J, Zhang L, Cong P, Yao Y, Sun G, et al. The combination of the tumor markers suggests the histological diagnosis of lung cancer. Biomed Res In 2017; 2017(1): 2013989.
  9. Kammer MN, Kussrow AK, Webster RL, Chen H, Hoeksema M, Christenson R, et al. Compensated interferometry measures of CYFRA 21–1 improve diagnosis of lung cancer. ACS Comb Sci 2019; 21(6): 465-72.
  10. Fu L, Wang R, Yin L, Shang X, Zhang R, Zhang P. CYFRA21-1 tests in the diagnosis of non-small cell lung cancer: a meta-analysis. Int J Biol Markers 2019; 34(3): 251-61.
  11. Chen F, Wang X-Y, Han X-H, Wang H, Qi J. Diagnostic value of Cyfra21-1, SCC and CEA for differentiation of early-stage NSCLC from benign lung disease. Int J Clin Exp Med 2015; 8(7): 11295.
  12. Song X, Wang S, Wang Z, Cao W, Chen F. Serum CYFRA21-1 as an effective tumor biomarker for patients with nasopharyngeal carcinoma. Neoplasma 2015; 62(1): 124-9.
  13. Song K-S, Nimse SB, Warkad SD, Oh A-C, Kim T, Hong YJ. Quantification of CYFRA 21-1 and a CYFRA 21-1–anti-CYFRA 21-1 autoantibody immune complex for detection of early stage lung cancer. Chemical Communications 2019; 55(68): 10060-3.
  14. Meng X, Chen X, Wu W, Zheng W, Deng H, Xu L, et al. Electrochemiluminescent immunoassay for the lung cancer biomarker CYFRA21-1 using MoO x quantum dots. Mikrochim Acta 2019; 186(12): 855.
  15. Okamura K, Takayama K, Izumi M, Harada T, Furuyama K, Nakanishi Y. Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer. Lung Cancer 2013; 80(1): 45-9.
  16. Pujol J-L, Boher J-M, Grenier J, Quantin X. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer 2001; 31(2-3): 221-31.
  17. Schneider J, Velcovsky H-G, Morr H, Katz N, Neu K, Eigenbrodt E. Comparison of the tumor markers tumor M2-PK, CEA, CYFRA 21-1, NSE and SCC in the diagnosis of lung cancer. Anticancer Res 2000; 20(6D): 5053-8.
Journal of Isfahan Medical School
Volume 43, Issue 815
3rd Week, July
July and August 2025
Pages 515-519

Files

History

  • Receive Date: 22 April 2025
  • Accept Date: 19 July 2025

Share

How to cite

Statistics